



## uniQure Announces Company Presentations at Upcoming October Conferences

October 2, 2017

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 02, 2017 (GLOBE NEWSWIRE) -- [uniQure N.V.](#) (NASDAQ:QURE) a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferences taking place in October:

### **Alliance for Regenerative Medicine (ARM) 2017 Cell & Gene Meeting on the Mesa, October 4 - 6 2017, at the Estancia La Jolla Hotel & Spa in La Jolla, California.**

- Jonathan Garen, chief business officer, will present a corporate overview on Wednesday, October 4<sup>th</sup>, 2017 at 3:30 p.m. PDT. The live webcast can be accessed through the link displayed in the [Investor section](#) of the uniQure website. The webcast replay will be available for at least two weeks following the live event.

### **European Society of Gene & Cell Therapy (EGSCT) 25<sup>th</sup> Anniversary Congress, October 17 - 20, 2017, at the BCC Berlin in Berlin, Germany.**

- Members of the uniQure research & development team will be presenting new data focused on the progress and optimization of uniQure's lead programs in gene therapy:
  - **Title:** *AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models*  
**Session Title:** 1b - Ocular and Central Nervous System Gene and Cell Therapy I  
**Date and Time:** Wednesday, October 18<sup>th</sup>, 2017, from 8:30 - 10:40 am CET
  - **Title:** *Engineered AAV capsids are successfully produced through the innovative approach of combining directed evolution and the BEVS expression system.*  
**Poster and Date:** P347 - Wednesday, October 18<sup>th</sup>, 2017.
  - **Title:** *Development and characterization of MFP-inducible GeneSwitch system for AAV5 gene therapy of chronic diseases in the liver*  
**Poster and Date:** P160 - Thursday, October 19<sup>th</sup>, 2017

### **4<sup>th</sup> Animal Models of Neurodegenerative Disease Conference, October 22 - 24, 2017, at Chateau Liblice, Czech Republic.**

- Members of the uniQure research & development team will be presenting new data focused on progress in technologies and development of animal models in gene therapy for Huntington's disease:
  - **Title:** *Establishing proof-of-concept of gene therapy for Huntington's disease.*  
**Date:** Tuesday, October 24<sup>th</sup>, 2017, morning session.
  - **Title:** *AAV-mediated delivery in large animals.*  
**Date:** Monday, October 23<sup>rd</sup>, 2017, afternoon session.

#### **About uniQure**

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases. [www.uniQure.com](http://www.uniQure.com)

#### **uniQure Contacts:**

##### **Maria E. Cantor**

Direct: 339-970-7536

Mobile: 617-680-9452

[m.cantor@uniQure.com](mailto:m.cantor@uniQure.com)

##### **Eva M. Mulder**

Direct: +31 20 240 6103

Mobile: +31 6 52 33 15 79

[e.mulder@uniQure.com](mailto:e.mulder@uniQure.com)

##### **Tom Malone**

Direct: 339-970-7558

Mobile: 339-223-8541

[t.malone@uniQure.com](mailto:t.malone@uniQure.com)